• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Charles River Labs Lowers Guidance, Acquires Two Companies

Charles River Labs Lowers Guidance, Acquires Two Companies

August 7, 2009
CenterWatch Staff

At the same timeCharles River Laboratories announced the acquisition of two companies, the preclinical contract research organization (CRO) lowered its full-year guidance for 2009.

In second-quarter financial results released earlier this week, Charles River’s net sales and income both decreased from the same period last year. Sales for the quarter fell 12.5% to $308.2 million, down from $352.1 million in the second quarter of 2008. Net income for Q2 2009 was $34.2 million, or $0.52 per diluted share, compared to net income of $49.1 million, or $0.70 per diluted share, last year.

The Wilmington, Mass.-based company reduced its full-year earnings per share estimate to be in the range of $1.78 to $1.90, down from the range $1.86 to $2.16.

Along with its second-quarter results, Charles River announced the recent acquisition of Finland-based Cerebricon, a discovery services provider, and the pending purchase of Systems Pathology Company (SPC), a pathology-based software provider.

Cerebricon was purchased for $9 million in cash and will become a part of Charles River Discovery and Imaging Services.

SPC will be acquired for an initial payment of approximately of $24 million with future payments based on certain undisclosed milestones. This deal is expected to close by the end of August.

“We have focused our efforts on identifying those assets and arrangements which we believe will position us to offer our clients novel solutions to the challenges of drug development. Each of these deals brings unique capabilities to Charles River, which we believe are a strategic advantage as we endeavor to offer value-added solutions,” Charles River chairman, president and CEO James Foster said in a statement.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing